Insights on the predictive accuracy of the sperm DNA fragmentation tests on male infertility

tau.amegroups.com © Translational Andrology and Urology. All rights reserved. Dr. El-Sakka in his commentary on the “Clinical utility of sperm DNA fragmentation testing: practice recommendations based on clinical scenarios” by Agarwal et al. (1), has generally acknowledged the importance of clinical scenarios in remedying the current sperm DNA fragmentation (SDF) debate and identifying the proper indications for performing the SDF testing method. He also addressed the current drawbacks of SDF that still impede its routine use in clinical practice. SDF test sensitivity and specificity in predicting male infertility as well as the burden of its cost were among the drawbacks discussed by Dr. Elsakka in his commentary. Conventional semen analysis remains the cornerstone of male fertility evaluation. However, despite its ability to provide an overall assessment of male fertility potential, it fails as an accurate predictor of fecundity. Notwithstanding the periodic refinements in semen analysis techniques and cutoff values in the form of WHO guidelines for semen assessment, up to 30% of men with normal semen parameters remain infertile (2). These findings have triggered the search for additional diagnostic tools that could improve our ability to predict pregnancy. Of all the sperm function tests, SDF is perhaps the only test that has withstood the test of time in terms of its applicability in male fertility evaluation. Since the first pioneering publication in Science with its cover photomicrograph showing florescent flow-cytometric red and green stained sperm and reporting a significant difference in sperm DNA integrity between fertile and subfertile bulls and men (3), the study of sperm DNA integrity has been constantly evolving. In the years since this first report, several other testing modalities were developed examining different aspects of sperm DNA damage that enhanced our understanding of the paternal genomic contribution to the fetus (1). At the same time, the preponderance of testing modalities having multiple cutoff values have been considered as a disadvantage to the applicability of SDF in clinical practice and was perhaps the principal factor behind failure of reproductive societies to advocate its routine use in the evaluation of male infertility (4). Recently, with the refinements in the testing methodologies and their performance in appropriate clinical scenarios, we are witnessing an improvement in SDF test validity and predictive accuracy (5-7) and are therefore expecting an update to the best practice recommendations. For example, TUNEL has been found to be a valid independent test of fertility capable of predicting pregnancy both naturally and after ART with a sensitivity of 85% and a specificity of 89% (8). A sperm chromatin dispersion (SCD) test cutoff value of 25.5% was found to have a sensitivity of 86.2% and a negative predictive value of 72.7% (P=0.02) in predicting successful ART treatment (9). Likewise, a sperm chromatin structure assay cutoff value of 30% was found to carry a significant predictive power to the likelihood of pregnancy both in vivo and after ART, where patients with a SDF <30% were 7.1 times [95% confidence interval (CI), 3.37–14.91] more likely to achieve a pregnancy in vivo and ~2.0 times (95% CI, 1.10–2.96) more likely to achieve pregnancy after ART (10). A recent meta-analysis examining Editorial